Estrella Immunopharma’s (ESLA) “Buy” Rating Reiterated at D. Boral Capital

Estrella Immunopharma (NASDAQ:ESLA)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a report issued on Monday,Benzinga reports. They presently have a $16.00 target price on the stock.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Estrella Immunopharma in a research note on Friday. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Estrella Immunopharma currently has a consensus rating of “Hold” and a consensus target price of $16.00.

Estrella Immunopharma Stock Up 9.9%

NASDAQ ESLA traded up $0.24 during trading hours on Monday, hitting $2.66. The company’s stock had a trading volume of 587,566 shares, compared to its average volume of 132,180. The stock has a fifty day moving average of $1.42 and a 200 day moving average of $1.11. The firm has a market capitalization of $98.60 million, a P/E ratio of -8.95 and a beta of 0.39. Estrella Immunopharma has a twelve month low of $0.70 and a twelve month high of $2.90.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.